Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 11, 2021 16:01 ET
|
Satsuma Pharmaceuticals
-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022- -Results expected in Q2 from ongoing Phase 1 trial to inform dose...
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
March 25, 2021 17:00 ET
|
Satsuma Pharmaceuticals
Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022 Closed $80 million private...
Satsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference
March 10, 2021 08:00 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present...
Satsuma Pharmaceuticals Announces $80 Million Private Placement Financing
March 01, 2021 07:00 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that it has agreed to sell...
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
March 01, 2021 07:00 ET
|
Satsuma Pharmaceuticals
-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022- -Proceeds from $80 million private placement and existing cash expected to fund...
Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
November 24, 2020 16:16 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will...
Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
November 10, 2020 16:02 ET
|
Satsuma Pharmaceuticals
Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 Cash, cash equivalents and marketable securities of $82.1 million as of...
Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences
November 02, 2020 16:35 ET
|
Satsuma Pharmaceuticals
- Credit Suisse - 29th Annual Healthcare Conference -November 9th -12th - Stifel 2020 Virtual Healthcare Conference -November 16th -18th SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE)...
Satsuma Pharmaceuticals Announces Topline Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of Migraine
September 10, 2020 08:00 ET
|
Satsuma Pharmaceuticals
Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two...
Satsuma Pharmaceuticals to Participate in September Virtual Investor Conferences
September 03, 2020 18:57 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that John Kollins, President...